Hefei Lifeon Pharmaceutical (003020.SZ): Application for registration and listing of Dapagliflozin metformin sustained-release tablets has been accepted.

Hefei Lifeon Pharmaceutical (003020.SZ) announced that recently, the company has received the "Acceptance Notice" for the application for the registration and listing of dapagliflozin and metformin prolonged-release tablets (I), dapagliflozin and metformin prolonged-release tablets (II), and dapagliflozin and metformin prolonged-release tablets (III) issued by the National Medical Products Administration. It is reported that dapagliflozin and metformin prolonged-release tablets are a fixed-dose combination formulation, composed of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin and the biguanide metformin hydrochloride, combining two different but complementary mechanisms of action for blood sugar reduction. Dapagliflozin lowers blood sugar by promoting urinary sugar excretion, while metformin primarily acts by inhibiting liver glucose output and improving insulin sensitivity. This combination therapy aims to provide more comprehensive and effective blood sugar control for adults with type 2 diabetes. This product is a prolonged-release combination formulation jointly developed by Bristol-Myers Squibb Company (BMS) and AstraZeneca AB (AZ). As of the date of this announcement, in addition to imported products, 8 domestic companies have received approval to market the same product.